A Randomized, Double-blinded, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of Three Topical Applications of KH001 in Providing Long-term Relief from Dentin Hypersensitivity
Latest Information Update: 01 Nov 2024
At a glance
- Drugs KH 001 HysensBio (Primary)
- Indications Dentin Sensitivity
- Focus Therapeutic Use
- Sponsors HysensBio
Most Recent Events
- 29 Oct 2024 Status changed from not yet recruiting to recruiting.
- 20 Jun 2024 New trial record